betmiga
Selected indexed studies
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. (Low Urin Tract Symptoms, 2023) [PMID:36863312]
- Activation of β3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue. (Cardiovasc Res, 2024) [PMID:39288197]
- Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. (World J Urol, 2024) [PMID:38431689]
_Worker-drafted node — pending editorial review._
Connections
betmiga is a side effect of
Sources
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. (2023) pubmed
- Activation of β3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue. (2024) pubmed
- Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. (2024) pubmed
- Mirabegron. (2015) pubmed
- Efficacy of Mirabegron and Propiverine Combination in the Treatment of Refractory Overactive Bladder. (2025) pubmed
- Mirabegron: Pediatric First Approval. (2021) pubmed
- Mirabegron: A Review in Overactive Bladder Syndrome. (2018) pubmed
- Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia. (2025) pubmed
- [Comprehensive pharmacologic management of overactive bladder]. (2017) pubmed
- Brown Adipose Tissue Activation in Humans Increases Plasma Levels of Lipid Mediators. (2024) pubmed